Osteoprotegerin is an independent predictor of vascular events in finnish adults with type 1 diabetes

Diabetes Care

Volumn 36, Issue 7, 2013, Pages 1827-1833

  Gordin, Daniel ^a,b   Soro Paavonen, Aino ^a,b   Thomas, Merlin C ^c   Harjutsalo, Valma ^a,b,d   Saraheimo, Markku ^a,b   Bjerre, Mette ^e,f   Forsblom, Carol ^a,b   Flyvbjerg, Allan ^e,f   Groop, Per Henrik ^a,b,c  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b FOLKHÄLSAN RESEARCH CENTER   (Finland)

^c BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^d NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^e AARHUS UNIVERSITY HOSPITAL   (Denmark)

^f AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; INSULIN; OSTEOPROTEGERIN;

ADULT; AGE; AMPUTATION; BLOOD ANALYSIS; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CONFERENCE PAPER; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DISEASE DURATION; DISEASE REGISTRY; ETHNIC GROUP; FEMALE; FINNISH; FOLLOW UP; HAZARD RATIO; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; ISCHEMIC HEART DISEASE; KIDNEY DYSFUNCTION; LEG REVASCULARIZATION; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MIDDLE AGED; MORTALITY; PERIPHERAL VASCULAR DISEASE; PREDICTION; TRIACYLGLYCEROL BLOOD LEVEL; WAIST HIP RATIO;

ADULT; ALBUMINURIA; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 1; FEMALE; FINLAND; HUMANS; MALE; OSTEOPROTEGERIN;

EID: 84886002138     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-2170     Document Type: Conference Paper

References (35)

1. Floege J, Ketteler M. Vascular calcification in patients with end-stage renal disease. Nephrol Dial Transplant 2004;19(Suppl. 5):V59-V66
2. Tyson KL, Reynolds JL, McNair R, Zhang Q, Weissberg PL, Shanahan CM. Osteo/ chondrocytic transcription factors and their target genes exhibit distinct patterns of expression in human arterial calcification. Arterioscler Thromb Vasc Biol 2003;23:489-494
3. Vaccarezza M, Bortul R, Fadda R, Zweyer M. Increased OPG expression and impaired OPG/TRAIL ratio in the aorta of diabetic rats. Med Chem 2007;3:387-391
4. SimonetWS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-319
5. Flyvbjerg A. Diabetic angiopathy, the complement system and the tumor necrosis factor superfamily. Nat Rev Endocrinol 2010;6:94-101
6. Anand DV, Lahiri A, Lim E, Hopkins D, Corder R. The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects. J AmColl Cardiol 2006;47:1850-1857
7. Tousoulis D, Siasos G, Maniatis K, et al. Serum osteoprotegerin and osteopontin levels are associated with arterial stiffness and the presence and severity of coronary artery disease. Int J Cardiol. 26 May 2012 [Epub ahead of print]
8. Vik A, Mathiesen EB, Johnsen SH, et al. Serum osteoprotegerin, sRANKL and carotid plaque formation and growth in a general populationdthe Tromsoφ study. J Thromb Haemost 2010;8:898-905
9. Jorsal A, Tarnow L, Flyvbjerg A, Parving HH, Rossing P, Rasmussen LM. Plasma osteoprotegerin levels predict cardiovascular and all-cause mortality and deterioration of kidney function in type 1 diabetic patients with nephropathy. Diabetologia 2008;51:2100-2107
10. Reinhard H, Lajer M, Gall MA, et al. Osteoprotegerin and mortality in type 2 diabetic patients. Diabetes Care 2010;33: 2561-2566
11. Groop PH, Thomas MC, Moran JL, et al.; FinnDiane Study Group. The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes. Diabetes 2009;58:1651-1658
12. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39(Suppl. 1):S1-S266
13. Levey AS, Stevens LA, Schmid CH, et al.; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604-612
14. Roφysland R, Masson S, Omland T, et al.; GISSI-HF Investigators. Prognostic value of osteoprotegerin in chronic heart failure: The GISSI-HFtrial.AmHeart J2010;160:286-293
15. Sund R. Quality of the Finnish Hospital Discharge Register: a systematic review. Scand J Public Health 2012;40:505-515
16. Kuha J. AIC and BIC. Comparisons of assumptions and performance. Sociol Methods Res 2004;33:188-229
17. GrambschPM, Therneau TM. Proportional hazards tests and diagnostics based uponweighted residuals. Biometrika 1994;81: 515-526
18. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. StatMed 1996;15:361-387
19. May S, Hosmer DW. Hosmer and Lemeshow type goodness-of-fit statistics for the Cox proprotional hazards model. In Handbook of Statistics, Volume 23: Advances in Survival Analysis. Balakrishnan N, Rao CR, Eds. Amsterdam, North Holland, 2004, p. 383-394
20. Royston P. Explained variation for survival models. Stata J 2006;6:83-96
21. Belsley DA. Conditioning Diagnostics: Collinearity andWeak Data in Regression. New York, Wiley-Interscience, 1991
22. Browner WS, Lui LY, Cummings SR. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin EndocrinolMetab 2001;86:631-637
23. Schoppet M, Sattler AM, Schaefer JR, Herzum M, Maisch B, Hofbauer LC. Increased osteoprotegerin serum levels in men with coronary artery disease. J ClinEndocrinol Metab 2003;88:1024-1028
24. Knudsen ST, Foss CH, Poulsen PL, Andersen NH, Mogensen CE, Rasmussen LM. Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications. Eur J Endocrinol 2003;149:39-42
25. Galluzzi F, Stagi S, Salti R, et al. Osteoprotegerin serum levels in children with type 1 diabetes: a potential modulating role in bone status. Eur J Endocrinol 2005;153:879-885
26. Hofbauer LC, Schoppet M. Osteoprotegerin: a link between osteoporosis and arterial calcification? Lancet 2001;358:257-259
27. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003;423:337-342
28. Schoppet M, Preissner KT, Hofbauer LC. RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol 2002;22:549-553
29. Olesen P, Ledet T, Rasmussen LM. Arterial osteoprotegerin: increased amounts in diabetes and modifiable synthesis from vascular smooth muscle cells by insulin and TNF-alpha. Diabetologia 2005;48: 561-568
30. Hofbauer LC, Shui C, Riggs BL, et al. Effects of immunosuppressants on receptor activator ofNF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells. Biochem Biophys Res Commun 2001;280:334-339
31. Bucay N, Sarosi I, Dunstan CR, et al. osteoprotegerin- deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998;12:1260-1268
32. Min H, Morony S, Sarosi I, et al. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med 2000;192:463-474
33. Secchiero P, Candido R, Corallini F, et al. Systemic tumor necrosis factor-related apoptosis-inducing ligand delivery shows antiatherosclerotic activity in apolipoproteinE-null diabetic mice. Circulation 2006;114:1522-1530
34. Candido R, Toffoli B, Corallini F, et al. Human full-length osteoprotegerin induces the proliferation of rodent vascular smooth muscle cells both in vitro and in vivo. J VascRes 2010;47:252-261
35. Rasmussen LM, Tarnow L, Hansen TK, Parving HH, Flyvbjerg A. Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patients. Eur J Endocrinol 2006;154:75-81